Applications of CRISPR Cas-9 in Ovarian Cancer Research

Fortner, R.T.; Poole, E.M.; Wentzensen, N.A.; Trabert, B.; White, E.; Arslan, A.A.; Patel, A.V.; Setiawan, V.W.; Visvanathan, K.; Weiderpass, E.; Adami, H.O.; Black, A.; Bernstein, L.; Brinton, L.A.; Buring, J.; Clendenen, T.V.; Fournier, A.; Fraser, G.; Gapstur, S.M.; Gaudet, M.M.; Giles, G.G.; Gram, I.T.; Hartge, P.; Hoffman-Bolton, J.; Idahl, A.; Kaaks, R.; Kirsh, V.A.; Knutsen, S.; Koh, W.P.; Lacey, J.V., Jr; Lee, I.M.; Lundin, E.; Merritt, M.A.; Milne, R.L.; Onland-Moret, N.C.; Peters, U.; Poynter, J.N.; Rinaldi, S.; Robien, K.; Rohan, T.; Sánchez, M.J.; Schairer, C.; Schouten, L.J.; Tjonneland, A.; Townsend, M.K.; Travis, R.C.; Trichopoulou, A.; Brandt, P.A.; Vineis, P.; Wilkens, L.; Wolk, A.; Yang, H.P.; Zeleniuch-Jacquotte, A.; Tworoger, S.S. Ovarian cancer risk factors by tumor aggressiveness: an analysis from the ovarian cancer cohort consortium. Int. J. Cancer, 2019, 145(1), 58-69.
[http://dx.doi.org/10.1002/ijc.32075] [PMID: 30561796]

Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]

Cabasag, C.J.; Butler, J.; Arnold, M.; Rutherford, M.; Bardot, A.; Ferlay, J.; Morgan, E.; Møller, B.; Gavin, A.; Norell, C.H.; Harrison, S.; Saint-Jacques, N.; Eden, M.; Rous, B.; Nordin, A.; Hanna, L.; Kwon, J.; Cohen, P.A.; Altman, A.D.; Shack, L.; Kozie, S.; Engholm, G.; De, P.; Sykes, P.; Porter, G.; Ferguson, S.; Walsh, P.; Trevithick, R.; Tervonen, H.; O’Connell, D.; Bray, F.; Soerjomataram, I. Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study. Gynecol. Oncol., 2020, 157(1), 234-244.
[http://dx.doi.org/10.1016/j.ygyno.2019.12.047] [PMID: 32005583]

Allemani, C.; Matsuda, T.; Di Carlo, V.; Harewood, R.; Matz, M. Nikšić; M.; Bonaventure, A.; Valkov, M.; Johnson, C.J.; Estève, J.; Ogunbiyi, O.J.; Azevedo e Silva, G.; Chen, W.Q.; Eser, S.; Engholm, G.; Stiller, C.A.; Monnereau, A.; Woods, R.R.; Visser, O.; Lim, G.H.; Aitken, J.; Weir, H.K.; Coleman, M.P.; Bouzbid, S.; Hamdi-Chérif, M.; Zaidi, Z.; Meguenni, K.; Regagba, D.; Bayo, S.; Cheick, B.T.; Manraj, S.S.; Bendahhou, K.; Fabowale, A.; Bradshaw, D.; Somdyala, N.I.M.; Kumcher, I.; Moreno, F.; Calabrano, G.H.; Espinola, S.B.; Carballo, Q.B.; Fita, R.; Diumenjo, M.C.; Laspada, W.D.; Ibañez, S.G.; Lima, C.A.; De Souza, P.C.F.; Del Pino, K.; Laporte, C.; Curado, M.P.; de Oliveira, J.C.; Veneziano, C.L.A.; Veneziano, D.B.; Latorre, M.R.D.O.; Tanaka, L.F.; Rebelo, M.S.; Santos, M.O.; Galaz, J.C.; Aparicio Aravena, M.; Sanhueza Monsalve, J.; Herrmann, D.A.; Vargas, S.; Herrera, V.M.; Uribe, C.J.; Bravo, L.E.; Garcia, L.S.; Arias-Ortiz, N.E.; Morantes, D.; Jurado, D.M.; Yépez Chamorro, M.C.; Delgado, S.; Ramirez, M.; Galán Alvarez, Y.H.; Torres, P.; Martínez-Reyes, F.; Jaramillo, L.; Quinto, R.; Castillo, J.; Mendoza, M.; Cueva, P.; Yépez, J.G.; Bhakkan, B.; Deloumeaux, J.; Joachim, C.; Macni, J.; Carrillo, R.; Shalkow Klincovstein, J.; Rivera Gomez, R.; Poquioma, E.; Tortolero-Luna, G.; Zavala, D.; Alonso, R.; Barrios, E.; Eckstrand, A.; Nikiforuk, C.; Noonan, G.; Turner, D.; Kumar, E.; Zhang, B.; McCrate, F.R.; Ryan, S.; MacIntyre, M.; Saint-Jacques, N.; Nishri, D.E.; McClure, C.A.; Vriends, K.A.; Kozie, S.; Stuart-Panko, H.; Freeman, T.; George, J.T.; Brockhouse, J.T.; O’Brien, D.K.; Holt, A.; Almon, L.; Kwong, S.; Morris, C.; Rycroft, R.; Mueller, L.; Phillips, C.E.; Brown, H.; Cromartie, B.; Schwartz, A.G.; Vigneau, F.; Levin, G.M.; Wohler, B.; Bayakly, R.; Ward, K.C.; Gomez, S.L.; McKinley, M.; Cress, R.; Green, M.D.; Miyagi, K.; Ruppert, L.P.; Lynch, C.F.; Huang, B.; Tucker, T.C.; Deapen, D.; Liu, L.; Hsieh, M.C.; Wu, X.C.; Schwenn, M.; Gershman, S.T.; Knowlton, R.C.; Alverson, G.; Copeland, G.E.; Bushhouse, S.; Rogers, D.B.; Jackson-Thompson, J.; Lemons, D.; Zimmerman, H.J.; Hood, M.; Roberts-Johnson, J.; Rees, J.R.; Riddle, B.; Pawlish, K.S.; Stroup, A.; Key, C.; Wiggins, C.; Kahn, A.R.; Schymura, M.J.; Radhakrishnan, S.; Rao, C.; Giljahn, L.K.; Slocumb, R.M.; Espinoza, R.E.; Khan, F.; Aird, K.G.; Beran, T.; Rubertone, J.J.; Slack, S.J.; Garcia, L.; Rousseau, D.L.; Janes, T.A.; Schwartz, S.M.; Bolick, S.W.; Hurley, D.M.; Whiteside, M.A.; Miller-Gianturco, P.; Williams, M.A.; Herget, K.; Sweeney, C.; Johnson, A.T.; Keitheri Cheteri, M.B.; Migliore Santiago, P.; Blankenship, S.E.; Farley, S.; Borchers, R.; Malicki, R.; Espinoza, J.R.; Grandpre, J.; Wilson, R.; Edwards, B.K.; Mariotto, A.; Lei, Y.; Wang, N.; Chen, J.S.; Zhou, Y.; He, Y.T.; Song, G.H.; Gu, X.P.; Mei, D.; Mu, H.J.; Ge, H.M.; Wu, T.H.; Li, Y.Y.; Zhao, D.L.; Jin, F.; Zhang, J.H.; Zhu, F.D.; Junhua, Q.; Yang, Y.L.; Jiang, C.X.; Biao, W.; Wang, J.; Li, Q.L.; Yi, H.; Zhou, X.; Dong, J.; Li, W.; Fu, F.X.; Liu, S.Z.; Chen, J.G.; Zhu, J.; Li, Y.H.; Lu, Y.Q.; Fan, M.; Huang, S.Q.; Guo, G.P.; Zhaolai, H.; Wei, K.; Zeng, H.; Demetriou, A.V.; Mang, W.K.; Ngan, K.C.; Kataki, A.C.; Krishnatreya, M.; Jayalekshmi, P.A.; Sebastian, P.; Nandakumar, A.; Malekzadeh, R.; Roshandel, G.; Keinan-Boker, L.; Silverman, B.G.; Ito, H.; Nakagawa, H.; Sato, M.; Tobori, F.; Nakata, I.; Teramoto, N.; Hattori, M.; Kaizaki, Y.; Moki, F.; Sugiyama, H.; Utada, M.; Nishimura, M.; Yoshida, K.; Kurosawa, K.; Nemoto, Y.; Narimatsu, H.; Sakaguchi, M.; Kanemura, S.; Naito, M.; Narisawa, R.; Miyashiro, I.; Nakata, K.; Sato, S.; Yoshii, M.; Oki, I.; Fukushima, N.; Shibata, A.; Iwasa, K.; Ono, C.; Nimri, O.; Jung, K.W.; Won, Y.J.; Alawadhi, E.; Elbasmi, A.; Ab Manan, A.; Adam, F.; Sanjaajmats, E.; Tudev, U.; Ochir, C.; Al Khater, A.M.; El Mistiri, M.M.; Teo, Y.Y.; Chiang, C.J.; Lee, W.C.; Buasom, R.; Sangrajrang, S.; Kamsa-ard, S.; Wiangnon, S.; Daoprasert, K.; Pongnikorn, D.; Leklob, A.; Sangkitipaiboon, S.; Geater, S.L.; Sriplung, H.; Ceylan, O.; Kög, I.; Dirican, O.; Köse, T.; Gurbuz, T.; Karaşahin, F.E.; Turhan, D.; Aktaş, U.; Halat, Y.; Yakut, C.I.; Altinisik, M.; Cavusoglu, Y.; Türkköylü, A.; Üçüncü, N.; Hackl, M.; Zborovskaya, A.A.; Aleinikova, O.V.; Henau, K.; Van Eycken, L.; Valerianova, Z.; Yordanova, M.R.; Šekerija, M.; Dušek, L.; Zvolský, M.; Storm, H.; Innos, K.; Mägi, M.; Malila, N.; Seppä, K.; Jégu, J.; Velten, M.; Cornet, E.; Troussard, X.; Bouvier, A.M.; Guizard, A.V.; Bouvier, V.; Launoy, G.; Arveux, P.; Maynadié, M.; Mounier, M.; Woronoff, A.S.; Daoulas, M.; Robaszkiewicz, M.; Clavel, J.; Goujon, S.; Lacour, B.; Baldi, I.; Pouchieu, C.; Amadeo, B.; Coureau, G.; Orazio, S.; Preux, P.M.; Rharbaoui, F.; Marrer, E.; Trétarre, B.; Colonna, M.; Delafosse, P.; Ligier, K.; Plouvier, S.; Cowppli-Bony, A.; Molinié, F.; Bara, S.; Ganry, O.; Lapôtre-Ledoux, B.; Grosclaude, P.; Bossard, N.; Uhry, Z.; Bray, F.; Piñeros, M.; Stabenow, R.; Wilsdorf-Köhler, H.; Eberle, A.; Luttmann, S.; Löhden, I.; Nennecke, A.L.; Kieschke, J.; Sirri, E.; Emrich, K.; Zeissig, S.R.; Holleczek, B.; Eisemann, N.; Katalinic, A.; Asquez, R.A.; Kumar, V.; Petridou, E.; Ólafsdóttir, E.J.; Tryggvadóttir, L.; Clough-Gorr, K.; Walsh, P.M.; Sundseth, H.; Mazzoleni, G.; Vittadello, F.; Coviello, E.; Cuccaro, F.; Galasso, R.; Sampietro, G.; Giacomin, A.; Magoni, M.; Ardizzone, A.; D’Argenzio, A.; Castaing, M.; Grosso, G.; Lavecchia, A.M.; Sutera Sardo, A.; Gola, G.; Gatti, L.; Ricci, P.; Ferretti, S.; Serraino, D.; Zucchetto, A.; Celesia, M.V.; Filiberti, R.A.; Pannozzo, F.; Melcarne, A.; Quarta, F.; Russo, A.G.; Carrozzi, G.; Cirilli, C.; Cavalieri d’Oro, L.; Rognoni, M.; Fusco, M.; Vitale, M.F.; Usala, M.; Cusimano, R.; Mazzucco, W.; Michiara, M.; Sgargi, P.; Boschetti, L.; Borciani, E.; Seghini, P.; Maule, M.M.; Merletti, F.; Tumino, R.; Mancuso, P.; Vicentini, M.; Cassetti, T.; Sassatelli, R.; Falcini, F.; Giorgetti, S.; Caiazzo, A.L.; Cavallo, R.; Cesaraccio, R.; Pirino, D.R.; Contrino, M.L.; Tisano, F.; Fanetti, A.C.; Maspero, S.; Carone, S.; Mincuzzi, A.; Candela, G.; Scuderi, T.; Gentilini, M.A.; Piffer, S.; Rosso, S.; Barchielli, A.; Caldarella, A.; Bianconi, F.; Stracci, F.; Contiero, P.; Tagliabue, G.; Rugge, M.; Zorzi, M.; Beggiato, S.; Brustolin, A.; Berrino, F.; Gatta, G.; Sant, M.; Buzzoni, C.; Mangone, L.; Capocaccia, R.; De Angelis, R.; Zanetti, R.; Maurina, A.; Pildava, S.; Lipunova, N.; Vincerževskiené, I.; Agius, D.; Calleja, N.; Siesling, S.; Larønningen, S.; Møller, B.; Dyzmann-Sroka, A.; Trojanowski, M.; Góźdź, S.; Mężyk, R.; Mierzwa, T.; Molong, L.; Rachtan, J.; Szewczyk, S.; Błaszczyk, J.; Kępska, K.; Kościańska, B.; Tarocińska, K.; Zwierko, M.; Drosik, K.; Maksimowicz, K.M.; Purwin-Porowska, E.; Reca, E.; Wójcik-Tomaszewska, J.; Tukiendorf, A.; Grądalska-Lampart, M.; Radziszewska, A.U.; Gos, A.; Talerczyk, M.; Wyborska, M.; Didkowska, J.A.; Wojciechowska, U.; Bielska-Lasota, M.; Forjaz de Lacerda, G.; Rego, R.A.; Bastos, J.; Silva, M.A.; Antunes, L.; Laranja Pontes, J.; Mayer-da-Silva, A.; Miranda, A.; Blaga, L.M.; Coza, D.; Gusenkova, L.; Lazarevich, O.; Prudnikova, O.; Vjushkov, D.M.; Egorova, A.G.; Orlov, A.E.; Kudyakov, L.A.; Pikalova, L.V.; Adamcik, J.; Safaei, D.C.; Primic-Žakelj, M.; Zadnik, V.; Larrañaga, N.; Lopez de Munain, A.; Herrera, A.A.; Redondas, R.; Marcos-Gragera, R.; Vilardell Gil, M.L.; Molina, E.; Sánchez Perez, M.J.; Franch Sureda, P.; Ramos Montserrat, M.; Chirlaque, M.D.; Navarro, C.; Ardanaz, E.E.; Guevara, M.M.; Fernández-Delgado, R.; Peris-Bonet, R.; Carulla, M.; Galceran, J.; Alberich, C.; Vicente-Raneda, M.; Khan, S.; Pettersson, D.; Dickman, P.; Avelina, I.; Staehelin, K.; Camey, B.; Bouchardy, C.; Schaffar, R.; Frick, H.; Herrmann, C.; Bulliard, J.L.; Maspoli-Conconi, M.; Kuehni, C.E.; Redmond, S.M.; Bordoni, A.; Ortelli, L.; Chiolero, A.; Konzelmann, I.; Matthes, K.L.; Rohrmann, S.; Broggio, J.; Rashbass, J.; Fitzpatrick, D.; Gavin, A.; Clark, D.I.; Deas, A.J.; Huws, D.W.; White, C.; Montel, L.; Rachet, B.; Turculet, A.D.; Stephens, R.; Chalker, E.; Phung, H.; Walton, R.; You, H.; Guthridge, S.; Johnson, F.; Gordon, P.; D’Onise, K.; Priest, K.; Stokes, B.C.; Venn, A.; Farrugia, H.; Thursfield, V.; Dowling, J.; Currow, D.; Hendrix, J.; Lewis, C. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125), 1023-1075.
[http://dx.doi.org/10.1016/S0140-6736(17)33326-3] [PMID: 29395269]

Brennan, A.; Brennan, D.; Rees, M.; Hickey, M. Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer. Int. J. Gynecol. Cancer, 2021, 31(3), 352-359.
[http://dx.doi.org/10.1136/ijgc-2020-002032]

Reid, F.; Bhatla, N.; Oza, A.M.; Blank, S.V.; Cohen, R.; Adams, T.; Benites, A.; Gardiner, D.; Gregory, S.; Suzuki, M.; Jones, A. The World ovarian cancer coalition every woman study: Identifying challenges and opportunities to improve survival and quality of life. Int. J. Gynecol. Cancer, 2021, 31(2), 238-244.
[http://dx.doi.org/10.1136/ijgc-2019-000983] [PMID: 32540894]

Yi, M.; Li, T.; Niu, M.; Luo, S.; Chu, Q.; Wu, K. Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: A population-based study. Biomark. Res., 2021, 9(1), 55.
[http://dx.doi.org/10.1186/s40364-021-00310-y] [PMID: 34233747]

Rafii, S.; Tashkandi, E.; Bukhari, N.; Al-Shamsi, H.O. Current status of CRISPR/Cas9 application in clinical cancer research: Opportunities and challenges. Cancers, 2022, 14(4), 947.
[http://dx.doi.org/10.3390/cancers14040947] [PMID: 35205694]

Suzuki, K.; Tsunekawa, Y.; Hernandez-Benitez, R.; Wu, J.; Zhu, J.; Kim, E.J.; Hatanaka, F.; Yamamoto, M.; Araoka, T.; Li, Z.; Kurita, M.; Hishida, T.; Li, M.; Aizawa, E.; Guo, S.; Chen, S.; Goebl, A.; Soligalla, R.D.; Qu, J.; Jiang, T.; Fu, X.; Jafari, M.; Esteban, C.R.; Berggren, W.T.; Lajara, J.; Nuñez-Delicado, E.; Guillen, P.; Campistol, J.M.; Matsuzaki, F.; Liu, G.H.; Magistretti, P.; Zhang, K.; Callaway, E.M.; Zhang, K.; Belmonte, J.C.I. In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature, 2016, 540(7631), 144-149.
[http://dx.doi.org/10.1038/nature20565] [PMID: 27851729]

Slaymaker, I.M.; Gao, L.; Zetsche, B.; Scott, D.A.; Yan, W.X.; Zhang, F. Rationally engineered Cas9 nucleases with improved specificity. Science, 2016, 351(6268), 84-88.
[http://dx.doi.org/10.1126/science.aad5227] [PMID: 26628643]

Jinek, M.; Chylinski, K.; Fonfara, I.; Hauer, M.; Doudna, J.A.; Charpentier, E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 2012, 337(6096), 816-821.
[http://dx.doi.org/10.1126/science.1225829] [PMID: 22745249]

Jiang, F.; Zhou, K.; Ma, L.; Gressel, S.; Doudna, J.A.A. Cas9–guide RNA complex preorganized for target DNA recognition. Science, 2015, 348(6242), 1477-1481.
[http://dx.doi.org/10.1126/science.aab1452] [PMID: 26113724]

Cong, L.; Ran, F.A.; Cox, D.; Lin, S.; Barretto, R.; Habib, N.; Hsu, P.D.; Wu, X.; Jiang, W.; Marraffini, L.A.; Zhang, F. Multiplex genome engineering using CRISPR/Cas systems. Science, 2013, 339(6121), 819-823.
[http://dx.doi.org/10.1126/science.1231143] [PMID: 23287718]

Mali, P.; Yang, L.; Esvelt, K.M.; Aach, J.; Guell, M.; DiCarlo, J.E.; Norville, J.E.; Church, G.M. RNA-guided human genome engineering via Cas9. Science, 2013, 339(6121), 823-826.
[http://dx.doi.org/10.1126/science.1232033] [PMID: 23287722]

Sánchez-Rivera, F.J.; Jacks, T. Applications of the CRISPR–Cas9 system in cancer biology. Nat. Rev. Cancer, 2015, 15(7), 387-393.
[http://dx.doi.org/10.1038/nrc3950] [PMID: 26040603]

Dever, D.P.; Bak, R.O.; Reinisch, A.; Camarena, J.; Washington, G.; Nicolas, C.E.; Pavel-Dinu, M.; Saxena, N.; Wilkens, A.B.; Mantri, S.; Uchida, N.; Hendel, A.; Narla, A.; Majeti, R.; Weinberg, K.I.; Porteus, M.H. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature, 2016, 539(7629), 384-389.
[http://dx.doi.org/10.1038/nature20134] [PMID: 27820943]

G/Medhin. T.M.; Chekol, A.E.; Sisay, T.; Berhane, N.; Bekele, T.; Asmamaw, D.T. Current applications and future perspectives of crispr-cas9 for the treatment of lung cancer. Biologics, 2021, 15, 199-204.

Sabit, H.; Abdel-Ghany, S.; Tombuloglu, H.; Cevik, E.; Alqosaibi, A.; Almulhim, F.; Al-Muhanaa, A. New insights on CRISPR/Cas9-based therapy for breast Cancer. Genes Environ., 2021, 43(1), 15.
[http://dx.doi.org/10.1186/s41021-021-00188-0] [PMID: 33926574]

Zhao, X.; Liu, L.; Lang, J.; Cheng, K.; Wang, Y.; Li, X.; Shi, J.; Wang, Y.; Nie, G.A. CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment. Cancer Lett., 2018, 431, 171-181.
[http://dx.doi.org/10.1016/j.canlet.2018.05.042] [PMID: 29870774]

Rao, C.V.; Janakiram, N.B.; Madka, V.; Kumar, G.; Scott, E.J.; Pathuri, G.; Bryant, T.; Kutche, H.; Zhang, Y.; Biddick, L.; Gali, H.; Zhao, Y.D.; Lightfoot, S.; Mohammed, A. Small-molecule inhibition of GCNT3 disrupts mucin biosynthesis and malignant cellular behaviors in pancreatic cancer. Cancer Res., 2016, 76(7), 1965-1974.
[http://dx.doi.org/10.1158/0008-5472.CAN-15-2820] [PMID: 26880801]

Yin, J.H.; Elumalai, P.; Kim, S.Y.; Zhang, S.Z.; Shin, S.; Lee, M.; Chung, Y.J. TNNC1 knockout reverses metastatic potential of ovarian cancer cells by inactivating epithelial-mesenchymal transition and suppressing F-actin polymerization. Biochem. Biophys. Res. Commun., 2021, 547, 44-51.
[http://dx.doi.org/10.1016/j.bbrc.2021.02.021] [PMID: 33592378]

Zhao, G.; Wang, Q.; Gu, Q.; Qiang, W.; Wei, J.J.; Dong, P.; Watari, H.; Li, W.; Yue, J. Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells. Oncotarget, 2017, 8(55), 94666-94680.
[http://dx.doi.org/10.18632/oncotarget.21863] [PMID: 29212257]

Zhao, Q.; Qian, Q.; Cao, D.; Yang, J.; Gui, T.; Shen, K. Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing. J. Ovarian Res., 2018, 11(1), 31.
[http://dx.doi.org/10.1186/s13048-018-0406-z] [PMID: 29685168]

Huo, W.; Zhao, G.; Yin, J.; Ouyang, X.; Wang, Y.; Yang, C.; Wang, B.; Dong, P.; Wang, Z.; Watari, H.; Chaum, E.; Pfeffer, L.M.; Yue, J. Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells. J. Cancer, 2017, 8(1), 57-64.
[http://dx.doi.org/10.7150/jca.16723] [PMID: 28123598]

Ji, L.; Zhao, G.; Zhang, P.; Huo, W.; Dong, P.; Watari, H.; Jia, L.; Pfeffer, L.M.; Yue, J.; Zheng, J. Knockout of MTF1 inhibits the epithelial to mesenchymal transition in ovarian cancer cells. J. Cancer, 2018, 9(24), 4578-4585.
[http://dx.doi.org/10.7150/jca.28040] [PMID: 30588241]

He, Z.Y.; Zhang, Y.G.; Yang, Y.H.; Ma, C.C.; Wang, P.; Du, W.; Li, L.; Xiang, R.; Song, X.R.; Zhao, X.; Yao, S.H.; Wei, Y.Q. In Vivo ovarian cancer gene therapy using CRISPR-Cas9. Hum. Gene Ther., 2018, 29(2), 223-233.
[http://dx.doi.org/10.1089/hum.2017.209] [PMID: 29338433]

Tröder, S.E.; Zevnik, B. History of genome editing: From meganucleases to CRISPR. Lab. Anim., 2021, 56(1), 60-68.
[PMID: 33622064]

Khan, S.H. Genome-editing technologies: Concept, pros, and cons of various genome-editing techniques and bioethical concerns for clinical application. Mol. Ther. Nucleic Acids, 2019, 16, 326-334.
[http://dx.doi.org/10.1016/j.omtn.2019.02.027] [PMID: 30965277]

Stoddard, B.L. Homing endonuclease structure and function. Q. Rev. Biophys., 2005, 38(1), 49-95.
[http://dx.doi.org/10.1017/S0033583505004063] [PMID: 16336743]

Hafez, M.; Hausner, G. Homing endonucleases: DNA scissors on a mission. Genome, 2012, 55(8), 553-569.
[http://dx.doi.org/10.1139/g2012-049] [PMID: 22891613]

Carroll, D. Genome engineering with zinc-finger nucleases. Genetics, 2011, 188(4), 773-782.
[http://dx.doi.org/10.1534/genetics.111.131433] [PMID: 21828278]

Urnov, F.D.; Rebar, E.J.; Holmes, M.C.; Zhang, H.S.; Gregory, P.D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet., 2010, 11(9), 636-646.
[http://dx.doi.org/10.1038/nrg2842] [PMID: 20717154]

Gaj, T.; Gersbach, C.A.; Barbas, C.F. III ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol., 2013, 31(7), 397-405.
[http://dx.doi.org/10.1016/j.tibtech.2013.04.004] [PMID: 23664777]

Becker, S.; Boch, J. Tale and Talen genome editing technologies. Gene and Genome Editing, 2021, 2, 100007.
[http://dx.doi.org/10.1016/j.ggedit.2021.100007]

Boettcher, M.; McManus, M.T. Choosing the right tool for the job: RNAi, Talen, or Crispr. Mol. Cell, 2015, 58(4), 575-585.
[http://dx.doi.org/10.1016/j.molcel.2015.04.028] [PMID: 26000843]

Hecker, M.; Wagner, A.H. Transcription factor decoy technology: A therapeutic update. Biochem. Pharmacol., 2017, 144, 29-34.
[http://dx.doi.org/10.1016/j.bcp.2017.06.122] [PMID: 28642036]

Mann, M.J.; Dzau, V.J. Therapeutic applications of transcription factor decoy oligonucleotides. J. Clin. Invest., 2000, 106(9), 1071-1075.
[http://dx.doi.org/10.1172/JCI11459] [PMID: 11067859]

Martínez, T.; Wright, N.; López-Fraga, M.; Jiménez, A.I.; Pañeda, C. Silencing human genetic diseases with oligonucleotide-based therapies. Hum. Genet., 2013, 132(5), 481-493.
[http://dx.doi.org/10.1007/s00439-013-1288-1] [PMID: 23494242]

Dey, S.; Soltani, M.; Singh, A. Enhancement of gene expression noise from transcription factor binding to genomic decoy sites. Sci. Rep., 2020, 10(1), 9126.
[http://dx.doi.org/10.1038/s41598-020-65750-2] [PMID: 32499583]

Robson, E.; Jeffs, A.; Eccles, M. Off-target response to decoy oligodeoxynucleotide treatment. Nat. Precedings, 2008, 1.

Agrawal, N.; Dasaradhi, P.V.N.; Mohmmed, A.; Malhotra, P.; Bhatnagar, R.K.; Mukherjee, S.K. RNA interference: Biology, mechanism, and applications. Microbiol. Mol. Biol. Rev., 2003, 67(4), 657-685.
[http://dx.doi.org/10.1128/MMBR.67.4.657-685.2003] [PMID: 14665679]

Schwarz, D.S.; Hutvágner, G.; Haley, B.; Zamore, P.D. Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol. Cell, 2002, 10(3), 537-548.
[http://dx.doi.org/10.1016/S1097-2765(02)00651-2] [PMID: 12408822]

Bai, Y.; Liu, Y.; Su, Z.; Ma, Y.; Ren, C.; Zhao, R.; Ji, H.L. Gene editing as a promising approach for respiratory diseases. J. Med. Genet., 2018, 55(3), 143-149.
[http://dx.doi.org/10.1136/jmedgenet-2017-104960] [PMID: 29301855]

Xiang, G.; Zhang, X.; An, C.; Cheng, C.; Wang, H. Temperature effect on CRISPR-Cas9 mediated genome editing. J. Genet. Genomics, 2017, 44(4), 199-205.
[http://dx.doi.org/10.1016/j.jgg.2017.03.004] [PMID: 28412228]

Shah, S.Z.; Rehman, A.; Nasir, H.; Asif, A.; Tufail, B.; Usama, M.; Jabbar, B. Advances in research on genome editing CRISPR-Cas9 technology. J. Ayub Med. Coll. Abbottabad, 2019, 31(1), 108-122.
[PMID: 30868795]

Guha, T.; Edgell, D. Applications of alternative nucleases in the age of CRISPR/Cas9. Int. J. Mol. Sci., 2017, 18(12), 2565.
[http://dx.doi.org/10.3390/ijms18122565] [PMID: 29186020]

Karthikeyan, S.; Russo, A.; Dean, M.; Lantvit, D.D.; Endsley, M.; Burdette, J.E. Prolactin signaling drives tumorigenesis in human high grade serous ovarian cancer cells and in a spontaneous fallopian tube derived model. Cancer Lett., 2018, 433, 221-231.
[http://dx.doi.org/10.1016/j.canlet.2018.07.003] [PMID: 29981811]

Cui, Y.; Wu, B.O.; Flamini, V.; Evans, B.A.J.; Zhou, D.; Jiang, W.G. Knockdown of EPHA1 using CRISPR/CAS9 suppresses aggressive properties of ovarian cancer cells. Anticancer Res., 2017, 37(8), 4415-4424.
[PMID: 28739735]

Yung, M.M.H.; Tang, H.W.M.; Cai, P.C.H.; Leung, T.H.Y.; Ngu, S.F.; Chan, K.K.L.; Xu, D.; Yang, H.; Ngan, H.Y.S.; Chan, D.W. GRO-α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade. Theranostics, 2018, 8(5), 1270-1285.
[http://dx.doi.org/10.7150/thno.22536] [PMID: 29507619]

Zhu, W.; Liu, C.; Lu, T.; Zhang, Y.; Zhang, S.; Chen, Q.; Deng, N. Knockout of EGFL6 by CRISPR/Cas9 mediated inhibition of tumor angiogenesis in ovarian cancer. Front. Oncol., 2020, 10, 1451.
[http://dx.doi.org/10.3389/fonc.2020.01451] [PMID: 32983976]

Wen, Y.; Hou, Y.; Yi, X.; Sun, S.; Guo, J.; He, X.; Li, T.; Cai, J.; Wang, Z. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells. Theranostics, 2021, 11(4), 1795-1813.
[http://dx.doi.org/10.7150/thno.48101] [PMID: 33408782]

Yi, Y.; Tsai, S.H.; Cheng, J.C.; Wang, E.Y.; Anglesio, M.S.; Cochrane, D.R.; Fuller, M.; Gibb, E.A.; Wei, W.; Huntsman, D.G.; Karsan, A.; Hoodless, P.A. APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner. Gynecol. Oncol., 2017, 147(3), 663-671.
[http://dx.doi.org/10.1016/j.ygyno.2017.10.016] [PMID: 29079036]

Fang, P.; De Souza, C.; Minn, K.; Chien, J. Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity. Commun. Biol., 2019, 2(1), 335.
[http://dx.doi.org/10.1038/s42003-019-0580-6] [PMID: 31508509]

Walton, J.; Blagih, J.; Ennis, D.; Leung, E.; Dowson, S.; Farquharson, M.; Tookman, L.A.; Orange, C.; Athineos, D.; Mason, S.; Stevenson, D.; Blyth, K.; Strathdee, D.; Balkwill, F.R.; Vousden, K.; Lockley, M.; McNeish, I.A. CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma. Cancer Res., 2016, 76(20), 6118-6129.
[http://dx.doi.org/10.1158/0008-5472.CAN-16-1272] [PMID: 27530326]

Yahata, T.; Mizoguchi, M.; Kimura, A.; Orimo, T.; Toujima, S.; Kuninaka, Y.; Nosaka, M.; Ishida, Y.; Sasaki, I.; Fukuda-Ohta, Y.; Hemmi, H.; Iwahashi, N.; Noguchi, T.; Kaisho, T.; Kondo, T.; Ino, K. Programmed cell death ligand 1 D isruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression. Cancer Sci., 2019, 110(4), 1279-1292.
[http://dx.doi.org/10.1111/cas.13958] [PMID: 30702189]

He, Y.J.; Meghani, K.; Caron, M.C.; Yang, C.; Ronato, D.A.; Bian, J.; Sharma, A.; Moore, J.; Niraj, J.; Detappe, A.; Doench, J.G.; Legube, G.; Root, D.E.; D’Andrea, A.D.; Drané, P.; De, S.; Konstantinopoulos, P.A.; Masson, J.Y.; Chowdhury, D. DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells. Nature, 2018, 563(7732), 522-526.
[http://dx.doi.org/10.1038/s41586-018-0670-5] [PMID: 30464262]

Norouzi-Barough, L.; Sarookhani, M.; Salehi, R.; Sharifi, M.; Moghbelinejad, S. CRISPR/Cas9, a new approach to successful knockdown of ABCB1/P-glycoprotein and reversal of chemosensitivity in human epithelial ovarian cancer cell line. Iran. J. Basic Med. Sci., 2018, 21(2), 181-187.
[PMID: 29456815]

Hirschhorn, T.; Levi-Hofman, M.; Danziger, O.; Smorodinsky, N.I.; Ehrlich, M. Differential molecular regulation of processing and membrane expression of Type-I BMP receptors: Implications for signaling. Cell. Mol. Life Sci., 2017, 74(14), 2645-2662.
[http://dx.doi.org/10.1007/s00018-017-2488-y] [PMID: 28357470]

Wang, X.; Wang, H.; Xu, B.; Jiang, D.; Huang, S.; Yu, H.; Wu, Z.; Wu, Q. Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer. Am. J. Transl. Res., 2019, 11(2), 1145-1153.
[PMID: 30899413]

Faddaoui, A.; Sheta, R.; Bachvarova, M.; Plante, M.; Gregoire, J.; Renaud, M.C.; Sebastianelli, A.; Gobeil, S.; Morin, C.; Ghani, K.; Bachvarov, D. Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells. Cell Cycle, 2017, 16(7), 693-706.
[http://dx.doi.org/10.1080/15384101.2017.1295181] [PMID: 28278050]

Kodama, M.; Kodama, T.; Newberg, J.Y.; Katayama, H.; Kobayashi, M.; Hanash, S.M.; Yoshihara, K.; Wei, Z.; Tien, J.C.; Rangel, R.; Hashimoto, K.; Mabuchi, S.; Sawada, K.; Kimura, T.; Copeland, N.G.; Jenkins, N.A. In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. Proc. Natl. Acad. Sci., 2017, 114(35), E7301-E7310.
[http://dx.doi.org/10.1073/pnas.1705441114] [PMID: 28811376]

Li, X.; Chen, W.; Zeng, W.; Wan, C.; Duan, S.; Jiang, S. microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP. Br. J. Cancer, 2017, 116(1), 66-76.
[http://dx.doi.org/10.1038/bjc.2016.379] [PMID: 27875524]

Chen, X.; Li, X.; Wang, X.; Zhu, Q.; Wu, X.; Wang, X. MUC16 impacts tumor proliferation and migration through cytoplasmic translocation of P120-catenin in epithelial ovarian cancer cells: an original research. BMC Cancer, 2019, 19(1), 171.
[http://dx.doi.org/10.1186/s12885-019-5371-4] [PMID: 30795761]

Ling, K.; Jiang, L.; Liang, S.; Kwong, J.; Yang, L.; Li, Y. PingYin; Deng, Q.; Liang, Z. Nanog interaction with the androgen receptor signaling axis induce ovarian cancer stem cell regulation: Studies based on the CRISPR/Cas9 system. J. Ovarian Res., 2018, 11(1), 36.
[http://dx.doi.org/10.1186/s13048-018-0403-2] [PMID: 29716628]

Lu, T.; Zhang, L.; Zhu, W.; Zhang, Y.; Zhang, S.; Wu, B.; Deng, N. CRISPR/Cas9-Mediated OC-2 editing inhibits the tumor growth and angiogenesis of ovarian cancer. Front. Oncol., 2020, 10, 1529.
[http://dx.doi.org/10.3389/fonc.2020.01529] [PMID: 32984003]

Jiang, Y.; Lim, J.; Wu, K.C.; Xu, W.; Suen, J.Y.; Fairlie, D.P. PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR. Br. J. Pharmacol., 2021, 178(4), 913-932.
[http://dx.doi.org/10.1111/bph.15332] [PMID: 33226635]

Qin, W.; Xiong, Y.; Chen, J.; Huang, Y.; Liu, T. DC-CIK cells derived from ovarian cancer patient menstrual blood activate the TNFR1-ASK1-AIP1 pathway to kill autologous ovarian cancer stem cells. J. Cell. Mol. Med., 2018, 22(7), 3364-3376.
[http://dx.doi.org/10.1111/jcmm.13611] [PMID: 29566310]

Binkhathlan, Z.; Lavasanifar, A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: Current status and future perspectives. Curr. Cancer Drug Targets, 2013, 13(3), 326-346.
[http://dx.doi.org/10.2174/15680096113139990076] [PMID: 23369096]

Walton, J.B.; Farquharson, M.; Mason, S.; Port, J.; Kruspig, B.; Dowson, S.; Stevenson, D.; Murphy, D.; Matzuk, M.; Kim, J.; Coffelt, S.; Blyth, K.; McNeish, I.A. CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Sci. Rep., 2017, 7(1), 16827.
[http://dx.doi.org/10.1038/s41598-017-17119-1] [PMID: 29203787]

Mittal, R.D.; Jaiswal, P.K.; Goel, A. Survivin: A molecular biomarker in cancer. Indian J. Med. Res., 2015, 141(4), 389-397.
[http://dx.doi.org/10.4103/0971-5916.159250] [PMID: 26112839]

Frazzi, R. BIRC3 and BIRC5: Multi-faceted inhibitors in cancer. Cell Biosci., 2021, 11(1), 8.
[http://dx.doi.org/10.1186/s13578-020-00521-0] [PMID: 33413657]

Wheatley, S.P.; Altieri, D.C. Survivin at a glance. J. Cell Sci., 2019, 132(7), jcs223826.
[http://dx.doi.org/10.1242/jcs.223826] [PMID: 30948431]

Kaubryte, J.; Lai, A.G. Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review. NPJ Precision. Oncol., 2022, 6(1), 27.

Li, F.; Aljahdali, I.; Ling, X. Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? J. Exp. Clin. Cancer Res., 2019, 38(1), 368.
[http://dx.doi.org/10.1186/s13046-019-1362-1] [PMID: 31439015]

Ran, F.A.; Hsu, P.D.; Lin, C.Y.; Gootenberg, J.S.; Konermann, S.; Trevino, A.E.; Scott, D.A.; Inoue, A.; Matoba, S.; Zhang, Y.; Zhang, F. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell, 2013, 154(6), 1380-1389.
[http://dx.doi.org/10.1016/j.cell.2013.08.021] [PMID: 23992846]

Cho, S.W.; Kim, S.; Kim, Y.; Kweon, J.; Kim, H.S.; Bae, S.; Kim, J.S. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res., 2014, 24(1), 132-141.
[http://dx.doi.org/10.1101/gr.162339.113] [PMID: 24253446]

Shen, B.; Zhang, W.; Zhang, J.; Zhou, J.; Wang, J.; Chen, L.; Wang, L.; Hodgkins, A.; Iyer, V.; Huang, X.; Skarnes, W.C. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat. Methods, 2014, 11(4), 399-402.
[http://dx.doi.org/10.1038/nmeth.2857] [PMID: 24584192]

Qi, Y.; Song, H.; Xiao, H.; Cheng, G.; Yu, B.; Xu, F.J. Fluorinated acid-labile branched hydroxyl-rich nanosystems for flexible and robust delivery of plasmids. Small, 2018, 14(42), 1803061.
[http://dx.doi.org/10.1002/smll.201803061] [PMID: 30238691]

Qi, Y.; Liu, Y.; Yu, B.; Hu, Y.; Zhang, N.; Zheng, Y.; Yang, M.; Xu, F.J. A lactose-derived CRISPR/Cas9 delivery system for efficient genome editing in vivo to treat orthotopic hepatocellular carcinoma. Adv. Sci., 2020, 7(17), 2001424.
[http://dx.doi.org/10.1002/advs.202001424] [PMID: 32995132]

Sharma, P.C.; Gupta, A. MicroRNAs: Potential biomarkers for diagnosis and prognosis of different cancers. Transl. Cancer Res., 2020, 9(9), 5798-5818.
[http://dx.doi.org/10.21037/tcr-20-1294] [PMID: 35117940]

Bartel, D.P. MicroRNAs. Cell, 2004, 116(2), 281-297.
[http://dx.doi.org/10.1016/S0092-8674(04)00045-5] [PMID: 14744438]

Hammond, S.M. An overview of microRNAs. Adv. Drug Deliv. Rev., 2015, 87, 3-14.
[http://dx.doi.org/10.1016/j.addr.2015.05.001] [PMID: 25979468]

O’Brien, J.; Hayder, H.; Zayed, Y.; Peng, C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front. Endocrinol., 2018, 9, 402.
[http://dx.doi.org/10.3389/fendo.2018.00402] [PMID: 30123182]

Dexheimer, P.J.; Cochella, L. MicroRNAs: From mechanism to organism. Front. Cell Dev. Biol., 2020, 8, 409.
[http://dx.doi.org/10.3389/fcell.2020.00409] [PMID: 32582699]

Xu, J.; Li, L.; Shi, P.; Cui, H.; Yang, L. The crucial roles of Bmi-1 in cancer: Implications in pathogenesis, metastasis, drug resistance, and targeted therapies. Int. J. Mol. Sci., 2022, 23(15), 8231.
[http://dx.doi.org/10.3390/ijms23158231] [PMID: 35897796]

Yang, G.F.; He, W.P.; Cai, M.Y.; He, L.R.; Luo, J.H.; Deng, H.X.; Guan, X.Y.; Zeng, M.S.; Zeng, Y.X.; Xie, D. Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma. BMC Cancer, 2010, 10(1), 133.
[http://dx.doi.org/10.1186/1471-2407-10-133] [PMID: 20377880]

Abd El hafez, A.; EL-Hadaad, H.A. Immunohistochemical expression and prognostic relevance of Bmi-1, a stem cell factor, in epithelial ovarian cancer. Ann. Diagn. Pathol., 2014, 18(2), 58-62.
[http://dx.doi.org/10.1016/j.anndiagpath.2013.11.004] [PMID: 24342665]

Ouyang, Q.; Liu, Y.; Tan, J.; Li, J.; Yang, D.; Zeng, F.; Huang, W.; Kong, Y.; Liu, Z.; Zhou, H.; Liu, Y. Loss of ZNF587B and SULF1 contributed to cisplatin resistance in ovarian cancer cell lines based on Genome-scale CRISPR/Cas9 screening. Am. J. Cancer Res., 2019, 9(5), 988-998.
[PMID: 31218106]

Zhang, H.; Qin, C.; An, C.; Zheng, X.; Wen, S.; Chen, W.; Liu, X.; Lv, Z.; Yang, P.; Xu, W.; Gao, W.; Wu, Y. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol. Cancer, 2021, 20(1), 126.
[http://dx.doi.org/10.1186/s12943-021-01431-6] [PMID: 34598686]

Guo, T.; Dong, X.; Xie, S.; Zhang, L.; Zeng, P.; Zhang, L. Cellular mechanism of gene mutations and potential therapeutic targets in ovarian cancer. Cancer Manag. Res., 2021, 13, 3081-3100.
[http://dx.doi.org/10.2147/CMAR.S292992] [PMID: 33854378]

Kim, B.; Kim, Y.; Shin, S.; Lee, S.T.; Cho, J.Y.; Lee, K.A. Application of CRISPR/Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer. Cancer Cell Int., 2022, 22(1), 82.
[http://dx.doi.org/10.1186/s12935-022-02504-2] [PMID: 35168603]

Bukowski, K.; Kciuk, M.; Kontek, R. Mechanisms of multidrug resistance in cancer chemotherapy. Int. J. Mol. Sci., 2020, 21(9), 3233.
[http://dx.doi.org/10.3390/ijms21093233] [PMID: 32370233]

Zhang, X.H.; Tee, L.Y.; Wang, X.G.; Huang, Q.S.; Yang, S.H. Off-target effects in CRISPR/Cas9-mediated Genome Engineering. Mol. Ther. Nucleic Acids, 2015, 4(11), e264.
[http://dx.doi.org/10.1038/mtna.2015.37] [PMID: 26575098]

Hsu, P.D.; Scott, D.A.; Weinstein, J.A.; Ran, F.A.; Konermann, S.; Agarwala, V.; Li, Y.; Fine, E.J.; Wu, X.; Shalem, O.; Cradick, T.J.; Marraffini, L.A.; Bao, G.; Zhang, F. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol., 2013, 31(9), 827-832.
[http://dx.doi.org/10.1038/nbt.2647] [PMID: 23873081]

Sternberg, S.H.; Redding, S.; Jinek, M.; Greene, E.C.; Doudna, J.A. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature, 2014, 507(7490), 62-67.
[http://dx.doi.org/10.1038/nature13011] [PMID: 24476820]

Charlesworth, C.T.; Deshpande, P.S.; Dever, D.P.; Camarena, J.; Lemgart, V.T.; Cromer, M.K.; Vakulskas, C.A.; Collingwood, M.A.; Zhang, L.; Bode, N.M.; Behlke, M.A.; Dejene, B.; Cieniewicz, B.; Romano, R.; Lesch, B.J.; Gomez-Ospina, N.; Mantri, S.; Pavel-Dinu, M.; Weinberg, K.I.; Porteus, M.H. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat. Med., 2019, 25(2), 249-254.
[http://dx.doi.org/10.1038/s41591-018-0326-x] [PMID: 30692695]

Ferdosi, S.R.; Ewaisha, R.; Moghadam, F.; Krishna, S.; Park, J.G.; Ebrahimkhani, M.R.; Kiani, S.; Anderson, K.S. Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes. Nat. Commun., 2019, 10(1), 1842.
[http://dx.doi.org/10.1038/s41467-019-09693-x] [PMID: 31015529]

Ihry, R.J.; Worringer, K.A.; Salick, M.R.; Frias, E.; Ho, D.; Theriault, K.; Kommineni, S.; Chen, J.; Sondey, M.; Ye, C.; Randhawa, R.; Kulkarni, T.; Yang, Z.; McAllister, G.; Russ, C.; Reece-Hoyes, J.; Forrester, W.; Hoffman, G.R.; Dolmetsch, R.; Kaykas, A. p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells. Nat. Med., 2018, 24(7), 939-946.
[http://dx.doi.org/10.1038/s41591-018-0050-6] [PMID: 29892062]

Haapaniemi, E.; Botla, S.; Persson, J.; Schmierer, B.; Taipale, J. CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response. Nat. Med., 2018, 24(7), 927-930.
[http://dx.doi.org/10.1038/s41591-018-0049-z] [PMID: 29892067]

Shalem, O.; Sanjana, N.E.; Hartenian, E.; Shi, X.; Scott, D.A.; Mikkelsen, T.S.; Heckl, D.; Ebert, B.L.; Root, D.E.; Doench, J.G.; Zhang, F. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science, 2014, 343(6166), 84-87.
[http://dx.doi.org/10.1126/science.1247005] [PMID: 24336571]